CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Millions		Total		Series D	Series G	Adjustment	Preferred Stock	Preferred Stock Series D	Common Stock	Common Stock Series G	Capital Surplus	Capital Surplus Series G	Retained Earnings	Retained Earnings Series D	Retained Earnings Adjustment	Accumulated Other Comprehensive Income (Loss)		Noncontrolling Interest
Preferred stock, balance, beginning of period (in shares) at Dec. 31, 2022							31,686,000
Common stock, balance, beginning of period (in shares) at Dec. 31, 2022									537,101,000
Balance, beginning of period at Dec. 31, 2022		$ 8,547				$ 4	$ 1,014		$ 336		$ 4,840		$ 3,430		$ 4	$ (1,368)	[1]	$ 295
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		255											251					4
Other comprehensive income (loss)		160														160	[1]
Cash dividends declared:
Preferred stock		(8)											(8)
Common stock		(82)											(82)
Common stock repurchased (in shares)									(159,000)
Common stock repurchased		(4)									(4)
Common stock issued for:
Stock options exercised and restricted stock awards (in shares)									677,000
Stock options exercised and restricted stock awards		5									5
Stock-based compensation expense		22									22
Dividends declared - noncontrolling interest of subsidiary preferred stock		(4)																(4)
Preferred stock, balance, ending of period (in shares) at Mar. 31, 2023							31,686,000
Common stock, balance, ending of period (in shares) at Mar. 31, 2023									537,619,000
Balance, ending of period at Mar. 31, 2023		8,895					$ 1,014		$ 336		4,863		3,595			(1,208)	[1]	295
Preferred stock, balance, beginning of period (in shares) at Dec. 31, 2022							31,686,000
Common stock, balance, beginning of period (in shares) at Dec. 31, 2022									537,101,000
Balance, beginning of period at Dec. 31, 2022		8,547				4	$ 1,014		$ 336		4,840		3,430		4	(1,368)	[1]	295
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		727
Other comprehensive income (loss)		(214)														(214)
Common stock issued for:
Series G preferred stock conversion		493
Preferred stock, balance, ending of period (in shares) at Sep. 30, 2023							26,750,000
Common stock, balance, ending of period (in shares) at Sep. 30, 2023									558,709,000
Balance, ending of period at Sep. 30, 2023		8,793					$ 520		$ 349		5,337		3,874			(1,582)	[1]	295
Preferred stock, balance, beginning of period (in shares) at Mar. 31, 2023							31,686,000
Common stock, balance, beginning of period (in shares) at Mar. 31, 2023									537,619,000
Balance, beginning of period at Mar. 31, 2023		8,895					$ 1,014		$ 336		4,863		3,595			(1,208)	[1]	295
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		329											325					4
Other comprehensive income (loss)		(151)														(151)	[1]
Cash dividends declared:
Preferred stock		(8)											(8)
Common stock		(82)											(82)
Series D preferred stock redemption (in shares)							(4,936,000)
Series D preferred stock redemption		(494)					$ (494)
Common stock repurchased (in shares)									(575,000)
Common stock repurchased		(5)									(5)
Common stock issued for:
Stock options exercised and restricted stock awards (in shares)									1,872,000
Stock options exercised and restricted stock awards		0
Series G preferred stock conversion (in shares)										19,743,000
Series G preferred stock conversion					$ 493					$ 12		$ 481
Stock-based compensation expense		(13)							$ 1		(14)
Dividends declared - noncontrolling interest of subsidiary preferred stock		(4)																(4)
Preferred stock, balance, ending of period (in shares) at Jun. 30, 2023							26,750,000
Common stock, balance, ending of period (in shares) at Jun. 30, 2023									558,659,000
Balance, ending of period at Jun. 30, 2023		8,960					$ 520		$ 349		5,325		3,830			(1,359)	[1]	295
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		142											137					5
Other comprehensive income (loss)		(223)														(223)	[1]
Cash dividends declared:
Preferred stock		(8)											(8)
Common stock		(85)											(85)
Common stock repurchased (in shares)									(17,000)
Common stock repurchased		0
Common stock issued for:
Stock options exercised and restricted stock awards (in shares)									67,000
Stock options exercised and restricted stock awards		0
Stock-based compensation expense		12									12
Dividends declared - noncontrolling interest of subsidiary preferred stock		(5)																(5)
Preferred stock, balance, ending of period (in shares) at Sep. 30, 2023							26,750,000
Common stock, balance, ending of period (in shares) at Sep. 30, 2023									558,709,000
Balance, ending of period at Sep. 30, 2023		8,793					$ 520		$ 349		5,337		3,874			(1,582)	[1]	295
Preferred stock, balance, beginning of period (in shares) at Dec. 31, 2023							26,750,000
Common stock, balance, beginning of period (in shares) at Dec. 31, 2023									558,839,000
Balance, beginning of period at Dec. 31, 2023		9,291				8	$ 520		$ 349		5,351		3,964		8	(1,188)	[2]	295
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		197											192					5
Other comprehensive income (loss)		(83)														(83)	[2]
Cash dividends declared:
Preferred stock		(8)											(8)
Common stock		(84)											(84)
Common stock repurchased (in shares)	[3]								(11,052,000)
Common stock repurchased	[3]	(159)							$ (7)		(152)
Excise tax on common stock repurchased		(2)									(2)
Common stock issued for:
Stock options exercised and restricted stock awards (in shares)									850,000
Stock options exercised and restricted stock awards		0
Stock-based compensation expense		18							$ 1		17
Dividends declared - noncontrolling interest of subsidiary preferred stock		(5)																(5)
Preferred stock, balance, ending of period (in shares) at Mar. 31, 2024							26,750,000
Common stock, balance, ending of period (in shares) at Mar. 31, 2024									548,637,000
Balance, ending of period at Mar. 31, 2024		9,173					$ 520		$ 343		5,214		4,072			(1,271)	[2]	295
Preferred stock, balance, beginning of period (in shares) at Dec. 31, 2023							26,750,000
Common stock, balance, beginning of period (in shares) at Dec. 31, 2023									558,839,000
Balance, beginning of period at Dec. 31, 2023		9,291				$ 8	$ 520		$ 349		5,351		3,964		$ 8	(1,188)	[2]	295
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		624
Other comprehensive income (loss)		199														199
Cash dividends declared:
Series D preferred stock redemption													(7)
Common stock issued for:
Series G preferred stock conversion		$ 0
Preferred stock, balance, ending of period (in shares) at Sep. 30, 2024		16,750		0			16,750,000
Common stock, balance, ending of period (in shares) at Sep. 30, 2024									532,181,000
Balance, ending of period at Sep. 30, 2024		$ 9,316					$ 426		$ 333		4,947		4,304			(989)	[2]	295
Preferred stock, balance, beginning of period (in shares) at Mar. 31, 2024							26,750,000
Common stock, balance, beginning of period (in shares) at Mar. 31, 2024									548,637,000
Balance, beginning of period at Mar. 31, 2024		9,173					$ 520		$ 343		5,214		4,072			(1,271)	[2]	295
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		204											199					5
Other comprehensive income (loss)		(10)														(10)	[2]
Cash dividends declared:
Preferred stock		(8)											(8)
Common stock		(84)											(84)
Series D preferred stock redemption (in shares)								(10,000,000)
Series D preferred stock redemption				$ (100)				$ (94)						$ (6)
Excise tax on preferred stock redemption		(1)											(1)
Common stock repurchased (in shares)	[3]								(14,896,000)
Common stock repurchased	[3]	(228)							$ (9)		(219)
Excise tax on common stock repurchased		(1)									(1)
Common stock issued for:
Stock options exercised and restricted stock awards (in shares)									3,135,000
Stock options exercised and restricted stock awards		2							$ 1		1
Stock-based compensation expense		13							$ 1		12
Dividends declared - noncontrolling interest of subsidiary preferred stock		(5)																(5)
Preferred stock, balance, ending of period (in shares) at Jun. 30, 2024							16,750,000
Common stock, balance, ending of period (in shares) at Jun. 30, 2024									536,876,000
Balance, ending of period at Jun. 30, 2024		8,955					$ 426		$ 336		5,007		4,172			(1,281)	[2]	295
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		223											218					5
Other comprehensive income (loss)		292														292	[2]
Cash dividends declared:
Preferred stock		(5)											(5)
Common stock		(81)											(81)
Common stock repurchased (in shares)	[3]								(4,743,000)
Common stock repurchased		(75)	[3]						$ (3)		(72)
Excise tax on common stock repurchased		(1)									(1)
Common stock issued for:
Stock options exercised and restricted stock awards (in shares)									48,000
Stock options exercised and restricted stock awards		0
Stock-based compensation expense		13									13
Dividends declared - noncontrolling interest of subsidiary preferred stock		$ (5)																(5)
Preferred stock, balance, ending of period (in shares) at Sep. 30, 2024		16,750		0			16,750,000
Common stock, balance, ending of period (in shares) at Sep. 30, 2024									532,181,000
Balance, ending of period at Sep. 30, 2024		$ 9,316					$ 426		$ 333		$ 4,947		$ 4,304			$ (989)	[2]	$ 295

[1] Due to the nature of the preferred stock issued by FHN and its subsidiaries, all components of other comprehensive income (loss) have been attributed solely to FHN as the controlling interest holder.

[2] Due to the nature of the preferred stock issued by FHN and its subsidiaries, all components of other comprehensive income (loss) have been attributed solely to FHN as the controlling interest holder.

[3] Includes $154 million, $212 million, and $75 million repurchased during first, second, and third quarter, respectively, under FHN's general purchase program